Oragenics
Adds Two New Independent Board Members
Dr.
Frederick W. Telling and Charles L. Pope Bring Invaluable Experience to the
Oragenics Board of Directors
For Immediate
Release
Tampa, FL (June 7, 2010) –
Oragenics, Inc. (OTCBB:
ORNI www.oragenics.com), a
biopharmaceutical company, announced today that Dr. Frederick W. Telling and
Charles L. Pope formally joined the Company's Board of Directors on Friday, June
4th, 2010 as independent directors.
David
Hirsch, the Company's CEO said, "Dr. Telling and Mr. Pope are excellent
additions to our Board. Dr. Telling brings a depth of experience in the
pharmaceuticals industry that will be invaluable to us as we continue to develop
our biotechnology assets. We are very excited to have Fred serve as
the new Chair of Oragenics’ Compensation Committee as well as a member of our
Audit Committee.. Mr. Pope is a former partner at PwC and has served as the CFO
for multiple public companies. We are equally pleased to have
Charlie’s decades of financial expertise to help us in our efforts to realize
Oragenics true potential. He will serve as the Chair of the Board’s audit
committee and as the committee’s designated financial exper, as well as be a
member of the Compensation Committee."
Mr.
Hirsch continued noting that “the addition of Mr. Pope and Dr. Telling as
independent directors and constituting the membership of the Company’s audit
committee, moves us closer toward meeting our Sarbanes Oxley compliance
objectives.”
Set forth
below is background information for Dr. Telling and Mr. Pope.
Frederick
W. Telling:
Prior to
retiring from Pfizer in
June 2007 after 30 years, Dr. Telling served as Corporate Vice President of
Pfizer Inc. and as Vice
President of Corporate Strategic Planning and Policy. Dr. Telling
oversaw the company’s realignment and focus on its human and animal health
business, which included the divestiture of its Food Science and Medical
Technology groups, while acquiring Warner Lambert, Pharmacia and various
consumer product brands. Concurrently, Fred was responsible for the company’s
policy development regarding the Prescription Drug User Fee Act’s original
passage and all of its subsequent reauthorizations, health care reform, pricing
and indigent access programs, and other issues. He represented the
company in many industry related outside Boards, including BIO where he served on its
Board for over 10 years. Dr. Telling is a Director of Cell Therapeutics Inc. based
in Seattle, Washington, Eisai
N.A. Inc. in Woodcliff Lake, New Jersey and MEDEX Global Group in
Baltimore, Maryland. Dr. Telling is a member of the Board of CED, IBM’s Healthcare & Life Sciences
Advisory Council, the
National March of Dimes Foundation, EAA, ORBIS and the United Hospital
Fund. He is also a member of the Metropolitan Club of
Washington, DC. Dr. Telling received his BA from Hamilton College and his
Master’s of Industrial and Labor Relations and Ph. D. in Economics and Public
Policy from Cornell
University.
Charles
L. Pope:
Mr. Pope
is a 30 year veteran in executive management, finance and accounting. During his
20 years at PricewaterhouseCoopers LLP,
Mr. Pope served as a Partner in the Audit and Financial Advisory Consulting
Divisions, and was a Partner in the Accounting and SEC Directorate. Currently,
Mr. Pope serves as the CFO and COO of the Palm Bank in Tampa, Florida.
Previously, he held CFO positions for public companies including, Aerosonic Corporation, Reptron Manufacturing and
SRI/Surgical Express.
He also served as CFO for UTEK
Corporation from 2001-2002. Mr. Pope is active in the community, having
served on Boards with such organizations as the Boy Scouts of America, Gulf
Ridge Council, Junior
Achievement of Tampa Bay, and Auburn University, Tampa Bay
chapter. He holds Bachelor of Science degrees in Economics and Accounting from
Auburn University, is a
Certified Public Accountant in Florida and a member of the American Institute of Certified
Public Accountants.
About
Oragenics, Inc.
Oragenics,
Inc. is a biopharmaceutical company engaged in the development of unique and
novel proprietary technologies, derived from the study of oral
biology. The Company's offerings include SMaRT Replacement Therapy™,
a one-time treatment that provides a potential life-time prevention of dental
caries (tooth decay), Mutacin 1140™ (MU 1140), an antibiotic that has proven
effective pre-clinically against Gram positive bacteria including MRSA, VRE and
Clostridium, the DPOLT™ synthetic chemistry platform that enables the Company to
produce MU 1140 and potentially the other 49 known lantibiotics, and ProBiora3®
a technology that whitens the teeth, freshens the breath and supports gum and
tooth health. ProBiora3® is incorporated into the Company's three
over-the-counter products; EvoraPlus® (www.evoraplus.com), EvoraKids® (www.evorakids.com) and Teddy's Pride™ (www.teddyspride.com). The company has
offices located at 3000 Bayport Drive, Suite 685, in Tampa, Florida 33607, and
in Progress Corporate Park at 13700 Progress Boulevard in Alachua, Florida
32615, approximately 15 miles from the campus of the University of Florida in
Gainesville.
# #
#
CONTACT:
|
Anthony
M. Giallourakis
|
Investor
Relations
Oragenics,
Inc.
(813)
220-6747
tgiallourakis@oragenics.com
Safe Harbor
Statement: Under the Private Securities Litigation Reform Act of 1995:
This release includes forward-looking statements that reflect the Company’s
current views with respect to future events and financial performance. These
forward-looking statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” "should," “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions that do
not relate solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking statements because
they are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not limited to those
factors set forth in our most recently filed annual report on Form 10-K and
quarterly report on Form 10-Q, and other factors detailed from time to time in
filings with the Securities and Exchange Commission. We expressly disclaim any
responsibility to update forward-looking statements.